INTRODUCTION {#sec1-1}
============

Ureteral colic is one of the most common urological emergencies. Apart from the size and location of the stone and the anatomy of the ureter, ureteral smooth muscle spasm is an important factor that determines the spontaneous passage of the stone.\[[@ref1][@ref2][@ref3]\] Drugs which produce ureteral relaxation have been used for medical expulsive therapy (MET) for ureteral calculi. Tamsulosin is the most commonly used drug for MET. Its action is site specific depending on the α-1 adrenergic receptor concentration. A recent study by Pickard *et al*.\[[@ref4]\] has questioned its role. There has been an increasing interest in the use of phosphodiesterase-5 (PDE-5) inhibitors in MET. Tadalafil, a PDE-5 inhibitor, has been used in combination with tamsulosin and has shown promising results.\[[@ref5]\] It acts by a nitric oxide/cyclic guanosine monophosphate (cGMP) signaling pathway of smooth muscles, inhibiting the degradation of cGMP, thus resulting in higher levels of intracellular cGMP.\[[@ref6][@ref7]\] cGMP is an important second messenger in intracellular signaling and causes ureteral smooth muscle relaxation. Reduction in ureteral smooth muscle tension has been seen with vardenafil, sildenafil, and tadalafil.\[[@ref6]\] Only a few *in vitro* studies have assessed the response of human ureteral muscles to tadalafil.\[[@ref8][@ref9]\] This study aimed to investigate the ability of tadalafil to relax the human ureter *in vitro*.

MATERIALS AND METHODS {#sec1-2}
=====================

Approval from the institutional review board (IRB No: 9460/05.06.2015) and informed written consent from all patients whose ureter was used for the study were obtained.

A total of 8 ureteral tissues (5 from radical nephrectomy specimens and 3 from live donor nephrectomy) were collected from patients after getting informed consent. Ureteral tissues of about 4 cm lengths were excised from macroscopically normal ureters during surgery and were immediately placed in freshly prepared mammalian ringer solution. Specimens were transported to the pharmacology laboratory from the operating room within 1 h after specimen retrieval, maintaining proper ambient temperature. Ureters which had gross inflammation or were dilated or involved with tumor were excluded from the study.

 {#sec2-1}

### Drugs used {#sec3-1}

All the salts required to prepare the mammalian ringer solution were purchased from Fischer chemical limited, Guangzhou, China. Tadalafil (Code No: CAS-171596-29-5) was purchased from Santa Cruz Biotechnology, USA. All the fine chemicals used in the study were obtained from Qualigens, Mumbai, India. We used potassium chloride (KCl) to induce contraction in the ureteral tissue, as it has been used since a long time to artificially activate smooth muscle by a highly reproducible mechanism that works through the activation of calcium channels leading to increases in cytosolic-free Ca^2+^ and activation of myosin light-chain kinase followed by contraction.\[[@ref10]\] KCl and tadalafil were dissolved in double-distilled water or dimethyl sulfoxide and made into stock solutions.

### Calibration studies {#sec3-2}

A total of 7 ureteral tissues were used in a pilot study to assess the effective concentration of drug for tissue response, time interval between adding the drugs into organ bath, and adequate length of ureter required. Separate ureteral tissues were used for the final study, and the parameters obtained from the pilot study were not used for the final statistical analysis.

Organ bath protocol *\[[Figure 1](#F1){ref-type="fig"}\]* {#sec2-2}
---------------------------------------------------------

After reaching the laboratory, periureteral tissue was dissected out and 2 cm of human ureteral tissue was prepared for the study. A Dale\'s organ bath was used for the study. Ureteral tissue was mounted in a 30 ml organ bath and continuously aerated with oxygen. The organ bath chamber contained mammalian ringer solution which was constituted of 9 g of NaCl, 0.42 g of KCl, 0.24 g of CaCl~2~, 0.5 g of NaHCO~3~, and 1 g of dextrose dissolved in 1000 ml of distilled water (unadjusted pH). The temperature of the organ bath medium was maintained at 37°C.

![Flow diagram of important steps in the study](IJU-34-287-g001){#F1}

A Physiograph was used for the study with 50 Hz filter and 100 mV/cm sensitivity. Speed limit of the Physiograph was set at 0.25 mm/s. First, 0.5 g of pretension was applied to the tissue and was allowed for stabilization for 30 min without any manipulation. Once the stable resting tone had been reached, ureteral contractions were induced by adding 80 mM KCl to the organ bath medium with a contact time of 90 s, and the baseline ureteral contractions were recorded.

The chamber was then washed four times every 5 min for the tissue to return to the stable resting tone. After a stable tone had been obtained again, the ureteral tissue was exposed to 20 μM tadalafil for a contact time of 5 min. Contractions were again induced by adding 80 mM KCl to the tadalafil medium and the response was observed for 90 s.

The chamber was again washed to clear tadalafil and KCl. Then, 80 mM KCl was added to induce baseline contractions once again which were considered as control for the next dose of tadalafil (40 μM). The chamber was washed again four times every 5 min. Once the tissue had achieved a stable resting tone, it was exposed to 40 μM tadalafil for 5 min, followed by the induction of contractions by adding 80 mM KCl.

### Statistical analysis {#sec3-3}

SPSS Statictics for Windows, version 18.0 (SPSS Inc., Chicago, Ill., USA) was used for the data analysis. Significance level was set at 5% to compare the outcomes between the groups. Median amplitude, median frequency, and median area under the contractility curve (AUCC) for KCl-induced contractions before and after exposure to different concentrations of the tadalafil were measured and analyzed using the Wilcoxon signed-rank test. The differences in the outcomes after exposure to different concentrations of tadalafil were analyzed using Mann--Whitney U-test.

RESULTS {#sec1-3}
=======

 {#sec2-3}

### Potassium chloride administration {#sec3-4}

Ureteral contractions were induced with 80 mM KCl, and three contractility parameters were measured: the amplitude, frequency, and AUCC. All the ureteral specimens responded well to KCl. A few ureters showed spontaneous contractions after mounting in organ bath medium until the completion of the study.

### Tadalafil {#sec3-5}

All three KCl-induced contractility parameters showed a statistically significant reduction after exposure to 20 μM tadalafil. The median amplitude and frequency of KCl-induced contractions and the median AUCC after exposure to 20 μM tadalafil (7.87 cm, 3.79/min, and 2.98 cm^2^, respectively) showed significant reduction compared to that of before exposure to tadalafil (9.37 cm, 4.48/min, and 4.50 cm^2^, respectively; *P* = 0,026, 0.008, and 0.008, respectively) \[[Table 1](#T1){ref-type="table"}, [Figure 2](#F2){ref-type="fig"} and [Graph 1](#F3){ref-type="fig"}\].

###### 

*In vitro* KCL-induced contractility parameters of human ureter before and after exposure to 20 μM tadalafil

![](IJU-34-287-g002)

![Potassium chloride-induced contractions of isolated mounted human ureteral tissue before and after exposure to 20 μM tadalafil](IJU-34-287-g003){#F2}

![*In vitro* potassium chloride-induced contractility parameters of human ureter before and after exposure to 20 μM tadalafil (Is the same graph printed twice?)](IJU-34-287-g004){#F3}

Similarly, after exposure to 40 μM tadalafil, the median amplitude and frequency of KCl-induced contractions and AUCC (4.50 cm, 2.56/min, and 0.92 cm^2^, respectively) showed significant reduction when compared to that of before exposure to tadalafil (7.62 cm, 3.88/min, and 3.32 cm^2^, respectively; *P* = 0,008, 0.016, and 0.008, respectively) \[[Table 2](#T2){ref-type="table"}, [Figure 3](#F4){ref-type="fig"} and [Graph 2](#F5){ref-type="fig"}\].

###### 

*In vitro* KCL-induced contractility parameters of human ureter before and after exposure to 40 μM tadalafil

![](IJU-34-287-g005)

![Potassium chloride-induced contractions of isolated mounted human ureteral tissue before and after exposure to 40 μM tadalafil](IJU-34-287-g006){#F4}

![*In vitro* potassium chloride-induced contractility parameters of human ureter before and after exposure to 40 μM tadalafil](IJU-34-287-g007){#F5}

However, when the reductions in KCl-induced contractility parameters after exposure to 20 μM and 40 μM tadalafil were compared, no statistically significant difference was seen (*P* = 0.065, 0.195, and 0.130, respectively, for median amplitude and frequency of KCl-induced contractions and AUCC) \[[Table 3](#T3){ref-type="table"} and [Graph 3](#F6){ref-type="fig"}\].

###### 

Comparison of reduction in *in vitro* KCL-induced contractility parameters of human ureter after exposure to tadalafil 20 μM and 40 μM

![](IJU-34-287-g008)

![Comparison of reduction in *in vitro* potassium chloride-induced contractility parameters of human ureter after exposure to tadalafil 20 μM and 40 μM](IJU-34-287-g009){#F6}

DISCUSSION {#sec1-4}
==========

Tadalafil, a PDE-5 inhibitor, is a well-known drug used in the management of erectile dysfunction. It attaches to the site on PDE enzyme where the cGMP breakdown happens, thereby inhibiting degradation of cGMP. An increase in cGMP leads to activation of cGMP-dependent protein kinases, which results in phosphorylation of the actin--myosin system and membrane-bound calcium channels. This leads to a reduction in the intracellular calcium levels and thus smooth muscle relaxation.\[[@ref11]\] Currently, PDE-5 inhibitors are widely used in urology for indications such as erectile dysfunction, benign prostatic enlargement with lower urinary tract symptoms, premature ejaculation, and severe overactive bladder and some studies showed a benefit in spontaneous passage of lower ureteral calculus.\[[@ref12]\] PDE-5 inhibitors are also used in the management of nonurological diseases such as congestive heart failure, diabetic neuropathy, diabetic retinopathy, Raynaud\'s phenomenon, digital arterial ischemia, and pulmonary arterial hypertension.\[[@ref7]\] As mentioned above, it appears that PDE-5 inhibitors have a safe clinical profile and hence many investigators consider that PDE-5 inhibitors can be used for ureteral colic.\[[@ref6]\] A few small-scale clinical studies showed some benefit of PDE-5 inhibitors in MET.\[[@ref13][@ref14]\]

A few *in vitro* studies using organ bath technique have shown that tension induced by KCL in isolated human ureteral tissue was reversed by inhibitors of different PDE isoenzymes including those of PDE-5.\[[@ref8][@ref9]\]

A study by Gratzke *et al*.\[[@ref8]\] investigated the effect of sildenafil, vardenafil, and tadalafil on isolated human ureteral segment and measured the levels cyclic adenosine monophosphate (cAMP) and cGMP by specific radioimmunoassay after administration of drugs into the organ bath. They were able to show a significant dose-dependent reversal of the ureteral tension induced by KCL. Among the tested PDE-5 inhibitors, vardenafil caused more accumulation of the cGMP than other PDE-5 inhibitors. Our results also showed a statistically significant reduction in ureteral contractility measured by the amplitude and frequency of contractions of isolated ureteral tissue and the AUCC with different concentrations of tadalafil compared to the controls \[Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}\].

Gratzke *et al*.\[[@ref8]\] and Liatsikos *et al*.\[[@ref15]\] showed that there was a dose-dependent response with PDE-5. The maximum concentration of PDE-5 inhibitors used was 10 μM in both the studies. In our study, increasing the concentration of tadalafil from 20 μM to 40 μM did not show a statistically significant incremental reduction of amplitude, frequency, and AUCC proportionally \[[Table 3](#T3){ref-type="table"}\]. Probably, the high affinity of tadalafil for intracellular receptors causes the slow dissociation of the drug from the receptors. Hence, the alteration of concentration of the drug may not give the effect through the receptor--ligand complex.\[[@ref16][@ref17][@ref18][@ref19]\] This effect may be significant clinically as increasing the dose may cause more adverse effects, rather than benefit. However, further studies are required to prove this effect.

All *in vitro* studies have inherent drawbacks. Tissue viability is the most important issue that requires attention. This drawback can only be minimized and cannot be completely eliminated. In our study, all the possible precautions were taken to minimize the tissue damage. Precautions were taken during the study to avoid excess tissue handling: tissue was transported in the physiological solution, which was prepared freshly on the day of the study; the study was started within an hour after retrieval from the patient; ureteral movement during the dissection (Kelly\'s sign) was present in all the tissues just before mounting on the organ bath medium; KCl solution was freshly prepared on the day of the procedure, so the possibility of contamination was minimized; there is frequent washing of the organ bath chamber with mammalian Ringer solution in between the drug administration to washout the metabolites, which may harm the tissue; tadalafil stock solution was prepared and stored at −20°C as per the recommendation of the pharmaceutical company; at the end of the study, KCl was added into the organ bath medium and ureteral contractions were noted in all the ureteral samples; and all ureteral studies were completed in 4 h. The measurement of cyclic nucleotides, cAMP and cGMP, would have been more informative for the present study.

Further, proximal ureteral tissue was used for the study. MET is generally indicated for distal ureteral calculi. The results from studies using proximal ureteral tissue may not be generalized to distal ureter.

CONCLUSION {#sec1-5}
==========

Tadalafil reduces the KCl-induced contractions of isolated human ureteral smooth muscle *in vitro*. No incremental relaxation of KCl-induced contractions occurred by increasing the dose of tadalafil from 20 μM to 40 μM. Prospective clinical trials are warranted to prove the applicability of tadalafil in MET.

**Financial support and sponsorship:** Institutional (Internal fluid grants).

**Conflicts of interest:** There are no conflicts of interest.
